Daiichi Sankyo UK, Limited: ENHERTU - (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
Reimbursement decisions in Scotland, Wales, and Northern Ireland to be announced later this year
Daiichi Sankyo UK, Limited
(hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in adults who have received two or more prior anti-HER2 based therapies.
In the UK, almost 54,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive.
Press release content from Business Wire. The AP news staff was not involved in its creation.
ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
April 20, 2021 GMT
Daiichi Sankyo UK, Limited (hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu ® (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in adults who have received two or more prior anti-HER2 based therapies.
In the UK, almost 54,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive. 1,2,3 The impact of the disease is significant, with breast cancer responsible for approximately 12,000 deaths per year. 1 There are an estimated 35,000 people living with metastatic breast
4.6 (8)
Kesimpta (ofatumumab) has been approved in the U.K. as the first self-administered, at-home, B-cell-targeting therapy for people with relapsing forms of multiple sclerosis (MS) and active disease.
More specifically, the approval includes patients with either clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS), who have been experiencing relapses or showing new lesions on MRI scans.
This approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) follows similar decisions in the E.U., the U.S., Canada, Switzerland, Singapore, Australia, Japan, Argentina, the United Arab Emirates, Albania, and India.
The U.K.’s National Institute for Health Care and Excellence (NICE) and the Scottish Medicines Consortium now will decide whether to add Kesimpta to their respective National Health Service (NHS), which would allow patients to access treatments at low or no cost. NICE’s decision is
Four medicines accepted for use by NHS Scotland
13th April 2021
The Scottish Medicines Consortium (SMC) has approved NHS funding for four new medicines, including treatments for multiple myeloma and severe migraine in its April 2020 decisions.
Firstly, Sanofi s Sarclisa (isatuximab) has been accepted by the SMC for the treatment of relapsed or refractory multiple myeloma, in combination with two other medicines - pomalidomide and dexamethasone.
This treatment was accepted following consideration through the SMC s Patient and Clinician Engagement (PACE) process, which is used for medicines for end of life and rare conditions.
Another medication developed by Sanofi - Dupixent (dupilumab) - was also accepted for use on NHS Scotland, for the treatment of a subgroup of patients with severe asthma.
Cannabis oil: Why won t NHS fund life-changing treatment for disabled Fife youngster? thecourier.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thecourier.co.uk Daily Mail and Mail on Sunday newspapers.